Introduction
In the late summer of 1967 a serious outbreak of an unknown infectious disease occurred in Germany and Yugoslavia. It affected 31 people, seven of whom died. A strange new RNA virus was isolated from the patients, and the source of the outbreak was traced to vervet monkeys (Cercopithecus aethiops) imported from Uganda. Since many of the cases were centred on the West German town of Marburg, the disease was designated Marburg disease.' The original outbreak subsided and no further cases were recognised until 1975, when a young man was Marburg virus morphologically but was serologically distinct.567
The name Ebola was given to the prototype strain.
Case report
On the 5 On the sixth day of illness, 16 November, a further 330 ml of convalescent serum from the Sudan, pretreated in the same manner, was infused and followed by Hartmann's solution to correct the dehydration. Next day his urinary output fell to its lowest volume of 830 ml despite adequate fluid replacement and a satisfactory blood pressure. At this stage his appetite began to return, but swallowing induced pain in the throat and behind the sternum. Examination showed extensive candidiasis. Diarrhoea and vomiting had become less frequent and ceased on the 18 November. The thrush responded to treatment with amphotericin B lozenges and the dysphagia settled within a few days. The erythematous stage of the rash began to fade on the 19 November, disclosing a petechial element over the limbs. On the same day he complained of stiffness of the small joints of his hands and to a lesser extent of the wrists and knees.
After 20 November his general condition improved. His fever subsided-to a low level, his energy began to return, and there was dramatic improvement in his interest and ability to concentrate, though he could barely recollect the acute phase of his illness. The joint symptoms did not persist. The temperature returned to normal on 22 November but there was a further slight flicker of fever on the next two days, after which the temperature remained normal (see figure) . Output of urine was normal by 23 November. At this stage it was decided to take specimens for clearance tests at weekly intervals and it was arbitrarily agreed that three negative sets of cultures from throat swab, blood, urine, and faeces would be an acceptable standard for discharging the patient from isolation. The discovery of virus in semen was not thought to justify further isolation, especially as the patient fully appreciated the implications. Subsequently he made an uneventful but slow recovery over 10 weeks. Sugar (mnuol/l) Conversion: SI to traditional units-Urea: 1 mmol/l 6 mg/lOO ml. Sugar: 1 mmol/1 z 18 mg/100 ml.
The Trexler negative-pressure plastic isolator and the techniques used for disposing of waste proved to be effective in preventing spread of Ebola virus from the patient to attendant staff and to the general community. Of the 24 nurses who were directly concerned in the care of the patient, six became ill with acute respiratory infections, which lasted on average two days. Four of the five doctors looking after the patient developed a 'flu-like illness with some gastrointestinal symptoms. At onset these illnesses caused concern but the problems invariably resolved within two or three days and antibody studies later showed no evidence of Ebola virus infection among either medical or nursing staff.
VIROLOGICAL INVESTIGATIONS
The first specimen of blood was collected about 14 hours after the patient became feverish; this was six days after the accident. This blood specimen was examined by electron microscopy and virus particles were seen which were similar to those of Ebola virus. Guinea-pigs inoculated with this blood specimen developed a febrile illness and electronmicroscope examination of their blood and tissues showed particles which were again similar to those of Ebola virus. These observations are consistent with an infection due to Ebola virus.
Virus isolations and serological studies were also made on specimens of blood collected daily during the acute phase of the illness and on blood, urine, faeces, throat swabs, and seminal fluid collected during the convalescent phase. The highest levels of virus in the blood (104-5 guinea-pig infective units/ml) were recorded on the first and second day of the illness. After the start of interferon treatment and serotherapy, the level dropped dramatically to 3-10 guinea-pig infective units/ml and remained at this level until the viraemia disappeared on the ninth day of illness (table II) .
No virus was isolated from faeces, urine, and throat swabs collected between days 14 and 27. Ebola virus was, however, isolated from specimens of seminal fluid collected on days 39 and 61 but not on days 76, 92, and 110.
After the infusion of 450 ml of convalescent serum (fluorescent antibody titre of 1/128-1/256) on day 2 circulating antibody levels of 1]16 were recorded in the patient's blood from days 3 to 9. This -increased to 1/32 on day 10 and gradually increased to a fluorescent antibody titre of 1/128 by day 34. The patient was then subjected to plasmapheresis between 16 and 25 February 1977. A total of seven units of plasma was taken, which resulted in the fluorescent antibody level dropping from 1/128 to 1/32, and a specimen of blood collected on 5 May 1977 had a fluorescent antibody titre of 1/16.
Discussion
The nature of the accident and the absence-of a visible puncture mark emphasise the invasiveness of Ebola virus and the high susceptibility of man. Although the new Ebola virus is serologically distinct from the original Marburg virus, the pattern of illness in our patient closely followed the course of Marburg disease as described in Germany and South Africa. The course and duration of the illness were similar and a characteristic clinical syndrome was produced by the exanthem, excessive fatigue, and considerable gastrointestinal disturbance. There were, however, some minor differences, notably the absence of headache and myalgia, which were prominent in Marburg and Johannesburg. The rash emerged after the standard prodromal period and had the morbilliform appearance described in the previous outbreaks of Marburg disease. The evolution of the rash differed from measles in that the lesions appeared first over 543 the back and not on the head and neck. A painful throat was not a feature of the early stage but-developed later when there was frank evidence of candidiasis.
While the course of the illness was milder than expected from reports elsew'here, the pattern and duration of symptoms were not modified. The relatively mild course of the illness and the absence of haemorrhage might have been determined by treatment with interferon and convalescent serum, but the value of these preparations could not be accurately assessed from experience-with one patient. Treatment was started with interferon 20 hours after the onset of illness and convalescent serum was first.given 47 hours after onset. There was no obvious clinical improvement after treatment, but there was a striking fall in the level of circulating virus. On the first day of illness a blood sample was found -to contain 104-5 guinea-pig infective units/ml; on the day after starting treatment with interferon there was no change in the amount of virus, but on the next day, after infusion of serum, the level in the-blood dropped to 10°5 guinea-pig infective units/ml. Since there is known to be a time lag before interferon produces an effect on vi-rus levels it is not possible to assess the relative effectiveness of the two preparations in clearing the blood. Subsequently virus was detected in low titre in the bloodstream throughout the acute stage of the illness but disappeared on the 9th day of illness, before the temperature had returned to normal (see figure) . The second infusion of serum had no effect on the amount of virus. The antibody levels achieved in the patient's blood after infusion were consistent with the dilution of the convalescent serum (table II) . The oliguria and proteinuria present at the height of the illness could have been attributed to deposition of immune complexes in the kidney, especially in view of the transient arthralgia at the end of the acute stage, but these features were recorded in severe cases during the original Marburg outbreak, when no serum was given.
Treatment of the convalescent serum to ensure safety presented serious problems. Marburg virus has been shown to persist in the body for se-veral months after the acute illness, though it has not been shown in the circulating blood. Marburg virus is relatively resistant to heat but is inactivated in serum maintained at 60°C for 60 minutes.10 The Ebola convalescent serum was therefore treated at this temperature for-60 minutes to ensure safety. The serum was also tested for-HBsAg and HBsAb because carriers are common in many parts of tropical Africa. During convalescence the patient's blood was found to be negative for HBsAg and HBsAb.
Blood examination during convalescence showed evidence of bone-marrow depression with a low haemoglobin concentration and low white blood cell count. These features were shown during the original outbreak of Marburg disease and were attributed to the activity of the virus. Interferon also causes bone-marrow depression affecting the stem cells of the granulocytes'-13 and synthesis of haemoglobin."4 Furthermore, interferon causes immunodepression1' and may have contributed to the severity of the thrush in our patient. Liver function tests during convalescence showed no evidence of liver damage.
In the early stage of the illness facilities were not available for conducting haematological or biochemical studies safely, so efforts were concentrated on establishing the virological diagnosis; in the late stage of the illness, when provision had been made for routine tests,16 they were not required for the management of the patient, though they proved useful for assessing the extent of damage during convalescence. Fortunately there was no bleeding and the use of prophylactic heparin was not considered to be necessary.
Once the haemoglobin and white blood cell levels had returned to normal plasmapheresis was performed to obtain a supply of convalescent serum. 
Summary
Twenty-five patients with acute myeloid leukaemia were treated with three quadruple drug combinations in predetermined rotation: TRAP (thioguanine, daunorubicin, cytarabine, prednisolone); COAP (cyclophosphamide, vincristine, cytarabine, prednisolone); and POMP (prednisolone, vincristine, methotrexate, mercaptopurine). Fifteen patients (60%) achieved complete remission and five (20%) partial remission. For maintenance, five-day courses of drugs were administered every 14 to 21 days and doses were increased to tolerance. The median length of complete remission was 66 weeks. -In eight patients remission maintenance treatment was discontinued and some remained in complete remission for over two years.
In this series the remission induction rate was comparable with that reported for other regimens and complete remission lasted longer with this intensive maintenance regimen than with others. Nevertheless, the Introduction Many regimens are used in the treatment of acute myeloid leukaemia (AML), but none has shown unique superiority.'-3 Intensive4 treatments have not proved greatly superior to nonintensive5 regimens. Complex remission maintenance using multiple drugs6 may be little better than simpler7 regimens. Remission-induction programmes have incorporated single drugs8 and combinations of seven9 or eight10 antileukaemic agents administered simultaneously. The complete remission rate in adults with AML has varied from 9 5%"" to 79% in different series.3 11 Higher complete remission rates have been reported for small groups of patients at specialised centres" 12 than for larger groups treated at many hospitals, where rates have varied from 9-5%" of 200 adults3 to 34% of 301 adults.'3 The importance of the choice of drugs and the intensity of treatment are outweighed by uncontrolled factors including patient selection and the differing capabilities of different institutions to give supportive care during the induction of remission. The complete remission rate in adults with AML has seldom exceeded 50% in a multicentre study and 65% in a specialised centre.
Attainment of complete remission in AML slightly improves survival. In large series the median duration of complete remission has varied from five to 11 months3 13-15; median survival has been longer but has seldom exceeded 13 months.3 Immunotherapy administered during remission of AML41 7 seems to prolong the short duration of survival after relapse but does not prolong the duration of complete remission. No regimen for remission maintenance in AML is definitely superior, and the advisability of attempting to maintain remission at all has been questioned.
